CD276 and cancer: MGA271, an Fc-optimized humanized mAb targeting B7-H3, has shown safety and antitumor efficacy in several tumor types that were refractory B7-H3-expressing cancers or where the vasculature of the patients with these cancers were positive for B7-H3, as revealed from an interim analysis of an ongoing dose-escalating phase I study (366).